Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Terminated2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

terminated250%
not_yet_recruiting250%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

NCT07557914
terminatedphase_3

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

NCT04925960
not_yet_recruitingphase_2

Research of SORD-CMT Natural History and Epalrestat Treatment

NCT05777226
terminatedphase_2

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

NCT03244358

Clinical Trials (4)

Showing 4 of 4 trials
NCT07557914Phase 2

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

Not Yet Recruiting
NCT04925960Phase 3

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Terminated
NCT05777226Phase 2

Research of SORD-CMT Natural History and Epalrestat Treatment

Not Yet Recruiting
NCT03244358Phase 2

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4